INS and diabetes mellitus: As demonstrated in a recent meta-analysis, SGLT-2i treatment is associated with increased plasma fasting glucagon levels in patients with diabetes compared with non-SGLT-2i treatments with a reduction of insulin and increased ketone body levels (91).